MOTS-c Peptide Therapy in Connecticut

MOTS-c peptide therapy helps restore mitochondrial function for better insulin sensitivity and vitality. In Stamford, CT, patients seek this treatment from integrative physicians like Dr. Henry Sobo to address age-related metabolic slowdown.

Exercise naturally raises MOTS-c levels, which decline after age 40, contributing to fatigue and weight gain. Therapy mimics this effect for sustainable benefits.

Understanding MOTS-c: The Exercise Mimic Peptide

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA-c, a 16-amino acid peptide produced by mitochondrial DNA. Unlike nuclear-encoded peptides, it translocates to the nucleus, influencing over 1,200 genes via AMPK activation.
Discovered in 2015 at USC, early studies showed it prevents diet-induced obesity in mice by enhancing fat oxidation.
Human plasma levels peak post-exercise, explaining its “exercise in a bottle” nickname.
Current research explores roles in diabetes, heart health, and neurodegeneration.

Core Benefits Backed by Science

MOTS-c offers multi-system support through mitochondrial signaling.

Metabolic Regulation

Improves skeletal muscle glucose uptake by 25-30% in models, rivaling metformin.
Reduces hepatic fat accumulation, aiding NAFLD.

Energy & Performance

Boosts endurance by 20%; aged mice ran 70% longer.
Raises AMPK for cellular energy homeostasis.

Anti-Aging & Longevity

Restores mitochondrial dynamics, countering age-related decline.
Lowers inflammation markers like IL-6.

Cardiovascular Protection

Attenuates ischemia-reperfusion injury in heart models.

Clinical trials (Phase 1/2) report improved HbA1c and fatigue scores in prediabetics.

MOTS-c in Relation to Muscle Homeostasis and Physical Activity

Mitochondria supply more energy to the muscles during exercise by communicating exercise-induced signals to other organs. MOTS-c administration and exercise training have an additive effect. MOTS-c treatment activates skeletal muscle AMPK, a well-known exercise regulator. Exercise is known to reduce the incidence of Type 2 diabetes and Cardiovascular Disease. It appears that MOTS-c therapy and regular aerobic exercise may reduce diabetic heart dysfunction through similar mechanisms. 

With advancing age there is an accumulation of DNA mutations, and resultant metabolic dysfunction, which are both inherent involved in the aging process. These mitochondrial genetic changes may contribute to the age-dependent decrease in MOTS-c levels.

Given that aging is associated with a decline of mitochondrial functions along with the development of aging-related diseases, and given that the tissue and circulating levels of MOTS-c fall with age, it is compelling to hypothesize that declining MDP levels are also related to age-related metabolic deterioration. This contributes to the scientific hypothesis that administration of MOTS-c may contribute mitochondrial homeostasis, and impart an anti-aging effect on those treated.

MOTS-c and other age-modifiers such as NAD+ share metabolic pathways. NAD+ also declines with age. Increasing its levels can also improve age-related disorders. This suggests that co-administration of these age modifiers may ad further clinical benefit. More clinical research is needed to refine therapeutic approaches based on the naturally produced peptides which decline with age.